Cartesian Therapeutics posts investor slides, outlook

Cartesian Therapeutics, Inc. filed a current report to furnish new investor materials.

Rhea-AI Filing Summary

Cartesian Therapeutics, Inc. filed a current report to furnish new investor materials. The company is making available a corporate slide presentation it uses at industry and investor conferences, attached as Exhibit 99.1, which provides updates and summaries of its business.

The company also issued a press release on January 9, 2026 highlighting recent progress and outlining its 2026 outlook, attached as Exhibit 99.2. These materials are furnished under Regulation FD, not deemed “filed” for liability purposes, and are not incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cartesian Therapeutics (RNAC) disclose in this 8-K filing?

The company furnished a Regulation FD update, providing its current corporate slide presentation used with the investment community as Exhibit 99.1 and a January 9, 2026 press release highlighting recent progress and its 2026 outlook as Exhibit 99.2.

What is Exhibit 99.1 in Cartesian Therapeutics' RNAC 8-K?

Exhibit 99.1 is a corporate slide presentation of Cartesian Therapeutics, Inc. dated January 2026, which the company presents or distributes at industry and other conferences to update investors on its business.

What is Exhibit 99.2 in Cartesian Therapeutics' RNAC 8-K?

Exhibit 99.2 is a press release of Cartesian Therapeutics, Inc. issued on January 9, 2026 that highlights recent company progress and outlines its 2026 outlook.

Are Cartesian Therapeutics' Exhibits 99.1 and 99.2 considered filed with the SEC?

No. The company states that the information in Item 7.01, including Exhibits 99.1 and 99.2, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to that section’s liabilities.

Can the RNAC slide deck and press release be incorporated by reference into other filings?

They are not deemed incorporated by reference into Securities Act or Exchange Act filings, except where another filing expressly sets forth a specific reference to incorporate the materials.

Does this Cartesian Therapeutics 8-K include financial statements?

Under Item 9.01, the company lists exhibits including the corporate slide presentation, the press release, and the cover page interactive data file; separate financial statements are not listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 08:06 AM Learn about SEC filing dates

0001453687false00014536872026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

CARTESIAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-37798

26-1622110

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

7495 New Horizon Way, Frederick, MD 21703

(Address of principal executive offices)(Zip Code)

(301) 348-8698

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock (Par Value $0.0001)			RNAC			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01. Regulation FD Disclosure.

Cartesian Therapeutics, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.1.

Additionally, on January 9, 2026, the Company issued a press release highlighting recent progress and outlining its 2026 outlook. This press release is attached to this Current Report on Form 8-K as Exhibit 99.2.

The information in Item 7.01 of this Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibits 99.1 or 99.2, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Exhibit Description
99.1						Corporate slide presentation of Cartesian Therapeutics, Inc. dated January 2026.
99.2						Press release of Cartesian Therapeutics, Inc. issued on January 9, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CARTESIAN THERAPEUTICS, INC.
Date: January 9, 2026			By:			/s/ Carsten Brunn, Ph.D.
						Carsten Brunn, Ph.D.
						President and Chief Executive Officer